Health Canada has instituted numerous measures to help address and combat COVID-19, from facilitating access to COVID-19 products to protecting the public from false or misleading advertisements claiming to prevent, treat or diagnose COVID-19 (see our previous bulletins on these issues in the “Health Canada's response to COVID-19” section).
Given the extensive measures instituted, Health Canada has also published documents summarizing its various measures. Health Canada’s regulatory response to COVID-19: Access to health products is one particularly helpful document.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More -
Ministerial Reliance Order permitting Health Canada to rely on decisions of foreign regulators now in force
On July 15, 2026, the Minister of Health’s Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs ("Reliance Order”) was pub...Read More -
Health Canada seeks feedback on pilot to prioritize domestically manufactured generic drug submissions
In a News Release dated July 15, 2026, Health Canada advised that it is modernizing its regulatory processes to improve efficiency while maintaining high standards for safety, efficacy and quality.Read More
